No Data
No Data
DBS has rated China Traditional Chinese Medicine (00570) as a "shareholding" and lowered the target price to HKD 4.9.
Daimler has lowered its profit forecast for trad chi med (00570) in China from 2024 to 2030 by 10% to 14%.
Dah Sing lowers target price of Trad Chi Med (00570.HK) to 4.9 yuan and adjusts profit forecast downwards.
In its report, Deutsche Bank lowered its profit forecast for China Traditional Chinese Medicine (00570.HK) from 2024 to 2030 by 10% to 14%, considering the monthly trend in the wake of the previous half-year's procurement price reduction. The reason is that the sales and gross margin forecast for the formula granules have been reduced. The target price has been lowered from HK$5.4 to HK$4.9. It is rated as "shareholding".
Express News | China Securities Co.,Ltd.: We recommend keeping confidence in the pharmaceutical industry in the second half of the year, waiting for the right time.
Hong Kong's pharmaceutical stocks rebounded today! After a deep adjustment from the beginning of the year until now, can they achieve a bottom-up rebound?
Since 2024, innovative drugs have received a variety of benefits from the policy combination. From multi-dimensional support for speeding up the registration and evaluation of innovative drugs, promoting multi-tiered innovation, and reasonable pricing of new drugs, the policy has moved from 'encouraging large-scale innovation' to 'encouraging high-quality innovation'.
Express News | Another Hong Kong pharmaceutical company is going private: Saisun Pharmaceuticals has officially delisted with a valuation of HKD 11.8 billion.
The National Medical Products Administration passed specialized regulations for traditional Chinese medicine standard management, which will take effect next year.
The National Medical Products Administration announced that the "Special Regulations for the Management of Chinese Medicine Standards" was reviewed and passed yesterday (4th) and will be implemented from 2025. The regulations aim to establish a strict drug standard system to address the issues of inconsistent quality and standards in the traditional Chinese medicine industry. It is expected to improve the quality standards of traditional Chinese medicine, ensure drug safety, and promote the standardized development of the TCM industry. In addition, the National Medical Products Administration also plans to carry out publicity and training to improve the ability and level of Chinese medicine standard management.
No Data